TITLE

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy

AUTHOR(S)
Rossi, Paolo Giorgi; Ricciardi, Alessandro; Cohet, Catherine; Palazzo, Fabio; Furnari, Giacomo; Valle, Sabrina; Largeron, Nathalie; Federici, Antonio
PUB. DATE
January 2009
SOURCE
BMC Public Health;2009, Vol. 9 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: We estimated the number of women undergoing cervical cancer screening annually in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of abnormalities. Methods: The annual number of screened women was estimated from National Health Interview data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and treatment costs were estimated using a typical disease management approach based on national guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs were obtained from Italian National Health Service and Hospital Information System of the Lazio Region. Results: An estimated 6.4 million women aged 25-69 years undergo screening annually in Italy (1.2 million and 5.2 million through organized and opportunistic screening programs, respectively). Approximately 2.4% of tests have positive findings. There are approximately 21,000 cases of CIN1 and 7,000-17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to €158.5 million for screening and €22.9 million for the management of cervical abnormalities. Conclusion: Although some cervical abnormalities might have been underestimated, the total annual cost of cervical cancer prevention in Italy is approximately €181.5 million, of which 87% is attributable to screening.
ACCESSION #
43226936

 

Related Articles

  • Cost‐effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. Kim, Jane J.; Leung, Gabriel M.; Woo, Pauline P. S.; Goldie, Sue J. // Journal of Public Health;Jun2004, Vol. 26 Issue 2, p130 

    Background To assess the cost‐effectiveness of alternative cervical cancer screening strategies to inform the design and implementation of a government‐sponsored population‐based screening programme in Hong Kong.

  • Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. Gomez, Jorge Alberto; Lepetic, Alejandro; Demarteau, Nadia // BMC Public Health;2014, Vol. 14 Issue 1, p1 

    Background In Chile, significant reductions in cervical cancer incidence and mortality have been observed due to implementation of a well-organized screening program. However, it has been suggested that the inclusion of human papillomavirus (HPV) vaccination for young adolescent women may be the...

  • Analyse coût-efficacité des stratégies de dépistage du cancer du col utérin en Tunisie. Lazaar, H. Ben Gobrane; Aounallah-Skhiri, H.; Oueslati, F.; Frikha, H.; Achour, N.; Hsairi, M. // Eastern Mediterranean Health Journal;jun2010, Vol. 16 Issue 6, p460 

    We aimed to identify the most appropriate screening strategy for cervical cancer (periodicity of 3, 5 or 10 years) for Tunisia, taking into consideration the incidence of the disease, costs of screening and economic implications. We simulated follow-up of a fictitious cohort of 1 million women...

  • Expenditure and resource utilisation for cervical screening in Australia. Jie-Bin Lew; Howard, Kirsten; Gertig, Dorota; Smith, Megan; Clements, Mark; Nickson, Carolyn; Ju-Fang Shi; Dyer, Suzanne; Lord, Sarah; Creighton, Prudence; Yoon-Jung Kang; Tan, Jeffrey; Canfell, Karen // BMC Health Services Research;2012, Vol. 12 Issue 1, p446 

    Background: The National Cervical Screening Program in Australia currently recommends that women aged 18-69 years are screened with conventional cytology every 2 years. Publicly funded HPV vaccination was introduced in 2007, and partly as a consequence, a renewal of the screening program that...

  • Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Kulasingam, Shalini L.; Benard, Steve; Barnabas, Ruanne V.; Largeron, Nathalie; Myers, Evan R. // Cost Effectiveness & Resource Allocation;2008, Vol. 6, Special section p1 

    Background: We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18) human papillomavirus (HPV) vaccine to the current screening programme in the UK compared to screening alone. Methods: A Markov model of the natural history of HPV infection incorporating screening and...

  • Pap smears cost-effective screening for high-risk elderly.  // Geriatrics;May1990, Vol. 45 Issue 5, p18 

    The article reports that Pap smear screening of elderly women is an effective and relatively low-cost method for lowering cervical cancer death rates. This is particularly true among high-risk individuals. The cost-effectiveness of cervical cancer screening was calculated as comparable to that...

  • Adjunctive HPV screening worth the extra cost in cervical cancer.  // PharmacoEconomics & Outcomes News;6/5/2004, Issue 454, p5 

    Reports on the benefits of cervical cytology screening strategies that incorporate human papillomavirus DNA testing in women in the U.S. Information on annual conventional cervical cytology; Decline in the risk of cervical cancer and medical cost when a programme of annual conventional Pap...

  • Cost analysis of different cervical cancer screening strategies in Mexico. Beal, Christyn M.; Salmerón, Jorge; Flores, Yvonne N.; Torres, Leticia; Granados-García, Víctor; Dugan, Ellen; Lazcano-Ponce, Eduardo // Salud Pública de México;sep/oct2014, Vol. 56 Issue 5, p492 

    Objective. To compare the costs and number of undetected cases of four cervical cancer screening strategies (CCSS) in Mexico. Materials and methods. We estimated the costs and outcomes of the following CCSS: a) conventional Papanicolaou smear (Pap) alone; b) high-risk human papilloma virus...

  • Cost of the Cervical Cancer Screening Program at the Mexican Social Security Institute. Granados-García, Víctor; Flores, Yvonne N.; Pérez, Ruth; Rudolph, Samantha E.; Lazcano-Ponce, Eduardo; Salmerón, Jorge // Salud Pública de México;sep/oct2014, Vol. 56 Issue 5, p502 

    Objective. To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS). Materials and methods. This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics